Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Captainblkon Dec 14, 2019 11:08am

38 Views

Post# 30455012

RE:NOBODY IS REMOTELY INTERESTED

DebbieTaylor174 wrote: Got the insiders scoop that nobody is interested whatsoever. It's a OTC PINK SHEET .03 stock with a very small sample size in the trials. Far below FDA recommendations. Plus kly is basically broke, 50 million in debt. well over half billion outstanding shares. Look at the last Quarterly financials it was HORRENDOUS!!! Going to ZERO

but your interested, and that's proof for me

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects